MAP1LC3B and colorectal carcinoma: TRAF6 can polyubiquitinate LC3B and promote LC3B-ATG7 complex formation to drive selective autophagic CTNNB1 degradation, beneficial for inhibiting cancer metastasis.149 However, in most clinical CRC, TRAF6 is phosphorylated at Thr266 by glycogen synthase kinase 3 beta (GSK3β), leading to increased K48-linked polyubiquitination and degradation, thereby inhibiting autophagy-dependent CTNNB1 reduction.149